Review

Oncology Reviews

, Volume 1, Issue 3, pp 141-151

Bisphosphonates: from preclinical evidence to survival data in the oncologic setting

  • Daniele SantiniAffiliated withMedical Oncology, University Campus Bio-Medico Email author 
  • , Sara GalluzzoAffiliated withMedical Oncology, University Campus Bio-Medico
  • , Maria Elisabetta FrattoAffiliated withMedical Oncology, University Campus Bio-Medico
  • , Bruno VincenziAffiliated withMedical Oncology, University Campus Bio-Medico
  • , Silvia AngelettiAffiliated withClinical Pathology, University Campus Bio-Medico
  • , Giordano DicuonzoAffiliated withClinical Pathology, University Campus Bio-Medico
  • , Gaia SchiavonAffiliated withMedical Oncology, University Campus Bio-Medico
  • , Giuseppe ToniniAffiliated withMedical Oncology, University Campus Bio-Medico

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Bisphosphonate therapy has become a standard of therapy for patients with malignant bone disease. In vivo pre-clinical data suggest that bisphosphonates may exert an antitumor effect and preliminary clinical data show promising activity on metastatic disease in cancer patients. This review will describe the pre-clinical evidence of action of bisphosphonates on osteoclasts and tumor cells, in both in vitro and animal models. In addition, the effects of principal bisphosphonates on skeletal disease progression in patients with cancers in different sites, including breast cancer, prostate cancer and non-small cell lung cancer will be reported. The preliminary clinical data from retrospective trials on the effect of bisphosphonates on survival will be described and the ongoing adjuvant phase III trial will be analyzed. This review will describe the preliminary clinical evidences from prospective studies on the effect of zoledronic acid treatment on the prevention of bone metastases.

Key words

Bisphosphonates Bone metastases Survival Preclinical